Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 12 01:41PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.85 Insider Own0.24% Shs Outstand26.84M Perf Week-0.15%
Market Cap1.05B Forward P/E12.30 EPS next Y3.18 Insider Trans0.00% Shs Float26.77M Perf Month0.93%
Income-49.69M PEG- EPS next Q-0.09 Inst Own3.25% Short Float0.03% Perf Quarter81.83%
Sales123.55M P/S8.50 EPS this Y94.69% Inst Trans- Short Ratio0.65 Perf Half Y59.94%
Book/sh0.42 P/B93.45 EPS next Y3677.88% ROA-30.08% Short Interest0.01M Perf Year131.27%
Cash/sh2.82 P/C13.86 EPS next 5Y- ROE-145.99% 52W Range15.25 - 41.90 Perf YTD52.00%
Dividend Est.- P/FCF- EPS past 5Y-22.85% ROI-46.74% 52W High-6.61% Beta1.76
Dividend TTM- Quick Ratio2.62 Sales past 5Y5635.44% Gross Margin95.01% 52W Low156.59% ATR (14)0.76
Dividend Ex-Date- Current Ratio2.69 EPS Y/Y TTM-27.77% Oper. Margin-34.02% RSI (14)66.92 Volatility0.86% 1.25%
Employees217 Debt/Eq8.46 Sales Y/Y TTM38.07% Profit Margin-40.22% Recom2.50 Target Price40.48
Option/ShortYes / Yes LT Debt/Eq8.46 EPS Q/Q-31.82% Payout- Rel Volume0.70 Prev Close39.06
Sales Surprise-21.02% EPS Surprise-348.01% Sales Q/Q55.07% EarningsMay 23 BMO Avg Volume14.15K Price39.13
SMA200.54% SMA5021.36% SMA20068.17% Trades Volume6,524 Change0.18%
Date Action Analyst Rating Change Price Target Change
Jun-20-23Initiated H.C. Wainwright Buy $60
Mar-01-23Initiated Guggenheim Neutral $18
Feb-26-21Initiated H.C. Wainwright Buy $52
Jul-01-20Initiated Citigroup Buy $36
Jun-30-20Initiated Jefferies Buy $44
Jul-04-24 03:44AM
Jun-18-24 06:25AM
Jun-17-24 12:01PM
May-30-24 02:20PM
May-28-24 08:46AM
07:27AM Loading…
May-23-24 09:53AM
May-16-24 11:29AM
May-15-24 08:30AM
07:52AM Loading…
May-14-24 07:52AM
May-06-24 02:16AM
Apr-24-24 01:35PM
Apr-18-24 07:13AM
Apr-09-24 07:24AM
Apr-08-24 08:38AM
Mar-11-24 09:28PM
Mar-06-24 02:34AM
Mar-01-24 07:39AM
Feb-22-24 11:15AM
Feb-21-24 01:45AM
Feb-14-24 01:11AM
Feb-13-24 11:26AM
02:31AM Loading…
Jan-08-24 02:31AM
Jan-07-24 11:19AM
Dec-27-23 12:16PM
Dec-20-23 09:30PM
Dec-11-23 09:38AM
Dec-01-23 03:21AM
Nov-30-23 02:49AM
Nov-24-23 03:10AM
Nov-07-23 10:29AM
Nov-06-23 08:00PM
Oct-27-23 03:27AM
Oct-23-23 09:33AM
Oct-19-23 03:58AM
Oct-05-23 04:42AM
Oct-04-23 07:30PM
Oct-03-23 04:20AM
Sep-29-23 08:17AM
Sep-28-23 06:22AM
Sep-27-23 01:33PM
Sep-19-23 10:37AM
Aug-20-23 08:20PM
Aug-18-23 04:21AM
Aug-17-23 08:40PM
Aug-15-23 04:52AM
Jul-13-23 02:20AM
Jun-21-23 04:12AM
May-30-23 10:18AM
May-16-23 01:14AM
May-05-23 09:01AM
Apr-28-23 04:54AM
Apr-26-23 10:40PM
Apr-11-23 09:43AM
Mar-31-23 11:24AM
Mar-13-23 01:15PM
Mar-12-23 11:15PM
Feb-23-23 01:41AM
Feb-02-23 03:46AM
Jan-31-23 02:22AM
Dec-30-22 03:03AM
Dec-20-22 10:08PM
Dec-13-22 03:04AM
Dec-09-22 02:10AM
Nov-15-22 02:45AM
Nov-14-22 01:11AM
Nov-07-22 03:15AM
Oct-21-22 09:12AM
Oct-19-22 10:09AM
Sep-20-22 09:29AM
Aug-18-22 01:16AM
Aug-15-22 09:55AM
Jul-29-22 06:26AM
Jul-28-22 09:55AM
Jul-17-22 08:00PM
Jul-15-22 11:19AM
Jul-11-22 07:00AM
Jul-07-22 08:00AM
Jun-30-22 04:35AM
Jun-28-22 06:26PM
Jun-03-22 08:00AM
May-19-22 03:21PM
May-18-22 01:30AM
May-17-22 05:18AM
Calliditas Therapeutics AB clinical-stage biopharmaceutical company. It engages in the identification, development, and commercialization of novel treatments in orphan indications. The firm focuses on renal and hepatic diseases with significant unmet medical needs. It offers Nefecon, a proprietary, novel oral formulation of budesonide for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN. The firm product TARPEYO is used to reduce proteinuria in adults with primary immunoglobulin. The company was founded by Mikael Bender and Bengt Ake Julander on February 20, 2004 and is headquartered in Stockholm, Sweden.